Eli Lilly and Company (LLY) – Monthly Stock Report
Publication Date: September 22, 2024
Company Overview
Eli Lilly and Company (LLY), based in Indianapolis, Indiana, is a leading name in the global pharmaceutical sector. Founded in 1876, Eli Lilly specializes in discovering, developing, and marketing a diverse range of medications, particularly targeting diabetes, oncology, and autoimmune diseases. Notable products such as Basaglar, Jardiance, and Taltz underpin its robust portfolio. The company is also at the forefront of innovative research, with initiatives in RNA and DNA-based therapies through its Lilly Seaport Innovation Center. With its strong revenue performance—approximately $38.92 billion—Eli Lilly stands out as a key player under the Pharmaceuticals sub-industry, marking itself an appealing investment opportunity with a bullish recommendation to buy and a target high share price set at $1,150.
Market Sentiment and Performance Metrics
As of now, Eli Lilly’s stock is trading at $921.49, showing positive momentum as it nears a fifty-two week high of $972.53. The stock’s current price exceeds its fifty-day moving average of $894.81, reflecting an upward trend over the last year, with the fifty-two week low recorded at $516.57. There are currently 900,425,984 shares outstanding, with only 0.78% of shares sold short, indicating strong market confidence in the company’s prospects. Analysts show optimism towards Eli Lilly, with a recommendation score averaging at 1.9 from 24 contributing analysts, solidifying the perspective of a favorable investment climate.
Growth Projections and Financial Analysis
Looking ahead, Eli Lilly’s future price projection suggests significant growth potential. Analysts have set a target high price at $1,150, with a mean target price of $1,003.35 and a median target price of $1,027.50. These projections, alongside robust financial results, demonstrate the company’s capability to capitalize on emerging opportunities within the healthcare landscape. However, a gap in key metrics, like the specific details of EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), limits insights into operational profitability.
Overall, Eli Lilly’s performance, market positioning, and strategic initiatives present a compelling narrative of growth and confidence for investors, making it a stock to watch in the pharmaceutical industry.
| Metric | Value |
|---|---|
| Market Cap | $829.7b |
| Total Debt | $29.0b |
| Total Cash | $3.4b |
| Shares Outstanding | 900.4m |
| Float Shares | 898.3m |
Disclaimer:
The information provided in this monthly report is for informational purposes only and should not be construed as financial, investment, or trading advice. AltStation.io does not guarantee the accuracy, completeness, or timeliness of the data and analyses presented. The content is based on publicly available information, and while we strive to ensure its accuracy, errors and omissions may occur.
Investing in stocks, cryptocurrencies, and other financial instruments involves significant risk, including the potential loss of principal. Past performance is not indicative of future results. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions. AltStation.io and its affiliates are not responsible for any losses incurred as a result of using this report.
By using this report, you acknowledge that you understand and accept these terms.